Cantor Fitzgerald Has Weak Forecast for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Soleno Therapeutics in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($2.85) per share for the year, down from their previous forecast of ($2.65). Cantor Fitzgerald has a "Overweight" rating and a $123.00 price target on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share.

A number of other research firms have also recently commented on SLNO. Robert W. Baird raised their target price on Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Lifesci Capital raised Soleno Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 4th. Guggenheim reaffirmed a "buy" rating and issued a $81.00 target price (up from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. UBS Group set a $105.00 price target on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Finally, HC Wainwright upped their price objective on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the stock a "buy" rating in a report on Monday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Soleno Therapeutics currently has an average rating of "Buy" and a consensus target price of $99.63.

Soleno Therapeutics Trading Down 2.0 %

Soleno Therapeutics stock traded down $1.51 during trading hours on Monday, hitting $72.16. 1,178,033 shares of the stock traded hands, compared to its average volume of 666,433. Soleno Therapeutics has a one year low of $36.61 and a one year high of $74.00. The firm's 50-day moving average price is $50.80 and its two-hundred day moving average price is $50.65. The company has a market cap of $3.31 billion, a PE ratio of -21.73 and a beta of -2.29.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41).

Insider Activity at Soleno Therapeutics

In other news, insider Kristen Yen sold 2,340 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total value of $108,061.20. Following the transaction, the insider now owns 76,605 shares in the company, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. The trade was a 54.78 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 945,012 shares of company stock valued at $64,166,842. 12.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Soleno Therapeutics

Hedge funds have recently bought and sold shares of the business. AlphaQuest LLC raised its stake in Soleno Therapeutics by 1,154.4% during the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after buying an additional 658 shares during the last quarter. US Bancorp DE bought a new position in Soleno Therapeutics in the fourth quarter worth approximately $34,000. Avanza Fonder AB purchased a new position in shares of Soleno Therapeutics during the 4th quarter worth $76,000. Springhill Fund Asset Management HK Co Ltd bought a new stake in shares of Soleno Therapeutics during the 4th quarter valued at $81,000. Finally, Avior Wealth Management LLC purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth $89,000. Hedge funds and other institutional investors own 97.42% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.